DexCom Company Leadership
| DXCM Stock | USD 134.30 0.44 0.33% |
DexCom's insiders are aggressively selling. The analysis of insiders' sentiment of trading DexCom Inc stock suggests that most insiders are panicking at this time. DexCom employs about 9.5 K people. The company is managed by 34 executives with a total tenure of roughly 247 years, averaging almost 7.0 years of service per executive, having 279.41 employees per reported executive.
| Kevin Sayer CEO CEO and President and Director |
| Jonathan Lord Chairman Independent Chairman of the Board |
DexCom's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-04-15 | Matthew Vincent Dolan | Disposed 1990 @ 137.81 | View | ||
| 2024-04-08 | Kevin R Sayer | Disposed 49633 @ 138.3 | View | ||
| 2024-03-28 | Michael Jon Brown | Disposed 2624 @ 140.04 | View | ||
| 2024-03-25 | Sadie Stern | Disposed 4137 @ 140 | View | ||
| 2024-03-12 | Sadie Stern | Disposed 20321 @ 133.61 | View | ||
| 2024-02-20 | Jereme M Sylvain | Disposed 3363 @ 116.73 | View | ||
| 2024-01-16 | Sadie Stern | Disposed 2902 @ 123.63 | View | ||
| 2023-12-12 | Steven R Altman | Disposed 3000 @ 120 | View | ||
| 2023-12-11 | Sadie Stern | Disposed 392 @ 117.66 | View | ||
| 2023-12-01 | Michael Jon Brown | Disposed 3612 @ 114.56 | View | ||
| 2023-11-24 | Steven Robert Pacelli | Disposed 411 @ 110.8 | View | ||
| 2023-11-22 | Sadie Stern | Disposed 1176 @ 110 | View | ||
| 2023-11-15 | Steven R Altman | Disposed 1000 @ 101.26 | View |
Monitoring DexCom's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
DexCom |
DexCom's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with DexCom's future performance. Based on our forecasts, it is anticipated that DexCom will maintain a workforce of about 9500 employees by May 2024.DexCom's latest congressional trading
Congressional trading in companies like DexCom Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in DexCom by those in governmental positions are based on the same information available to the general public.
| 2023-09-12 | Representative Josh Gottheimer | Disposed Under $15K | Verify | ||
| 2021-07-01 | Representative Kevin Hern | Acquired $100K to $250K | Verify | ||
| 2021-02-16 | Representative Peter Meijer | Disposed Under $15K | Verify | ||
| 2020-12-22 | Representative Gilbert Cisneros | Disposed Under $15K | Verify | ||
| 2020-10-02 | Representative Susie Lee | Disposed Under $15K | Verify | ||
| 2020-03-17 | Senator Tina Smith | Acquired $250K to $500K | Verify | ||
| 2019-06-20 | Representative Bradley S. Schneider | Disposed $100K to $250K | Verify |
DexCom Management Team Effectiveness
The company has return on total asset (ROA) of 0.0641 % which means that it generated a profit of $0.0641 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2578 %, meaning that it created $0.2578 on every $100 dollars invested by stockholders. DexCom's management efficiency ratios could be used to measure how well DexCom manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to grow to 0.09. Also, Return On Capital Employed is likely to grow to 0.13. At this time, DexCom's Intangible Assets are very stable compared to the past year. As of the 19th of April 2024, Return On Tangible Assets is likely to grow to 0.09, while Debt To Assets are likely to drop 0.41.As of the 19th of April 2024, Net Income Applicable To Common Shares is likely to grow to about 412 M, while Common Stock Shares Outstanding is likely to drop about 246.4 M.
DexCom Workforce Comparison
DexCom Inc is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 217,358. DexCom holds roughly 9,500 in number of employees claiming about 4% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.15 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.21 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.21. DexCom Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DexCom insiders, such as employees or executives, is commonly permitted as long as it does not rely on DexCom's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, DexCom insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 0.3667 | 11 | 30 | 292,181 | 218,471 |
| 2023-09-01 | 0.1538 | 2 | 13 | 5,552 | 16,127 |
| 2023-06-01 | 0.6296 | 17 | 27 | 58,760 | 106,231 |
| 2023-03-01 | 0.2692 | 14 | 52 | 407,732 | 328,234 |
| 2022-12-01 | 0.1667 | 1 | 6 | 31,449 | 29,425 |
| 2022-09-01 | 0.5 | 2 | 4 | 5,599 | 3,553 |
| 2022-06-01 | 1.4167 | 17 | 12 | 16,534 | 9,271 |
| 2022-03-01 | 0.2542 | 15 | 59 | 123,407 | 65,191 |
| 2021-12-01 | 0.0845 | 6 | 71 | 15,042 | 32,436 |
| 2021-09-01 | 0.0208 | 2 | 96 | 2,885 | 75,435 |
| 2021-06-01 | 0.3864 | 17 | 44 | 32,980 | 96,591 |
| 2021-03-01 | 0.1857 | 13 | 70 | 147,055 | 151,265 |
| 2020-12-01 | 0.0704 | 5 | 71 | 38,706 | 59,604 |
| 2020-09-01 | 0.0187 | 2 | 107 | 8,127 | 153,139 |
| 2020-06-01 | 0.1579 | 15 | 95 | 26,205 | 94,536 |
| 2020-03-01 | 0.0897 | 14 | 156 | 149,650 | 226,296 |
| 2019-12-01 | 0.0189 | 1 | 53 | 18,377 | 90,214 |
| 2019-09-01 | 0.0282 | 2 | 71 | 7,497 | 153,443 |
| 2019-06-01 | 0.28 | 14 | 50 | 45,617 | 98,582 |
| 2019-03-01 | 0.2121 | 14 | 66 | 210,700 | 194,083 |
| 2018-12-01 | 0.0526 | 3 | 57 | 33,484 | 125,961 |
| 2018-09-01 | 0.0824 | 7 | 85 | 96,115 | 339,118 |
| 2018-06-01 | 0.8148 | 22 | 27 | 161,146 | 320,577 |
| 2018-03-01 | 0.3667 | 11 | 30 | 427,238 | 124,397 |
| 2017-12-01 | 0.2 | 2 | 10 | 35,000 | 41,040 |
| 2017-09-01 | 0.1071 | 3 | 28 | 74,524 | 104,949 |
| 2017-06-01 | 0.55 | 11 | 20 | 76,221 | 115,583 |
| 2017-03-01 | 0.3429 | 36 | 105 | 502,692 | 658,670 |
| 2016-12-01 | 0.1667 | 4 | 24 | 21,000 | 111,964 |
| 2016-09-01 | 0.1667 | 15 | 90 | 180,335 | 821,915 |
| 2016-06-01 | 0.359 | 14 | 39 | 231,746 | 437,942 |
| 2016-03-01 | 0.3111 | 14 | 45 | 407,771 | 312,677 |
| 2015-12-01 | 0.3768 | 26 | 69 | 234,001 | 577,077 |
| 2015-09-01 | 0.2537 | 17 | 67 | 306,828 | 834,921 |
| 2015-06-01 | 0.4141 | 41 | 99 | 390,988 | 1,036,088 |
| 2015-03-01 | 0.4568 | 37 | 81 | 542,727 | 553,180 |
| 2014-12-01 | 0.473 | 35 | 74 | 510,630 | 1,051,923 |
| 2014-09-01 | 0.434 | 46 | 106 | 545,017 | 1,164,853 |
| 2014-06-01 | 0.5882 | 30 | 51 | 251,994 | 471,232 |
| 2014-03-01 | 0.5052 | 49 | 97 | 1,230,047 | 1,362,007 |
| 2013-12-01 | 0.4 | 20 | 50 | 258,376 | 643,041 |
| 2013-06-01 | 0.4615 | 6 | 13 | 97,339 | 171,353 |
| 2013-03-01 | 0.5333 | 8 | 15 | 584,850 | 148,960 |
| 2012-06-01 | 0.6667 | 4 | 6 | 88,826 | 69,741 |
| 2012-03-01 | 0.7 | 7 | 10 | 535,684 | 51,654 |
| 2010-06-01 | 14.0 | 28 | 2 | 115,680 | 6,606 |
| 2010-03-01 | 13.0 | 13 | 1 | 474,250 | 10,000 |
| 2009-12-01 | 18.0 | 18 | 1 | 93,245 | 3,861 |
| 2009-06-01 | 5.0 | 20 | 4 | 273,721 | 70,000 |
| 2008-09-01 | 1.0 | 4 | 4 | 160,000 | 27,500 |
| 2007-12-01 | 7.0 | 7 | 1 | 189,937 | 24,427 |
| 2007-09-01 | 3.6667 | 22 | 6 | 155,000 | 39,500 |
| 2007-06-01 | 13.0 | 13 | 1 | 1,166,221 | 26,255 |
| 2006-06-01 | 1.0 | 20 | 20 | 341,388 | 2,921,328 |
| 2006-03-01 | 0.2889 | 13 | 45 | 126,577 | 99,972 |
| 2005-12-01 | 0.375 | 18 | 48 | 281,858 | 2,669,646 |
| 2005-06-01 | 0.9348 | 43 | 46 | 19,114,425 | 17,306,408 |
DexCom Notable Stakeholders
A DexCom stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as DexCom often face trade-offs trying to please all of them. DexCom's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting DexCom's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Kevin Sayer | CEO and President and Director | Profile | |
| Jonathan Lord | Independent Chairman of the Board | Profile | |
| Terrance Gregg | Executive Chairman | Profile | |
| Lanny Roper | CFO, Vice President | Profile | |
| Patrick Murphy | Chief Compliance Officer, Vice President General Counsel | Profile | |
| Donald Abbey | Executive Vice President Quality and Information Technology | Profile | |
| Jake Leach | Senior Vice President of Research and Development | Profile | |
| Richard Doubleday | Senior Vice President - Worldwide Sales and Marketing | Profile | |
| Jeffrey Moy | Senior Vice President - Operations | Profile | |
| Heather Ace | Senior Vice President Human Resources | Profile | |
| John Lister | Senior Vice President General Counsel | Profile | |
| Andrew Balo | Senior Vice President - Clinical and Regulatory Affairs | Profile | |
| Jess Roper | CFO and Sr. VP | Profile | |
| Quentin Blackford | CFO | Profile | |
| Kevin Sun | Interim CFO | Profile | |
| Jacob Leach | Executive COO | Profile | |
| Girish Naganathan | Executive CTO | Profile | |
| Jorge Valdes | Chief Technical Officer and Executive VP | Profile | |
| Steven Pacelli | Executive VP of Strategy and Corporate Devel. | Profile | |
| Eric Topol | Independent Director | Profile | |
| Mark Foletta | Independent Director | Profile | |
| Jay Skyler | Independent Director | Profile | |
| Nicholas Augustinos | Independent Director | Profile | |
| Richard Collins | Independent Director | Profile | |
| Barbara Kahn | Independent Director | Profile | |
| Steven Altman | Independent Director | Profile | |
| Shelly Selvaraj | Senior Officer | Profile | |
| Matthew Dolan | Corporate Strategy | Profile | |
| Paul Flynn | Ex Revenue | Profile | |
| Michael Brown | Executive Officer | Profile | |
| Sean Christensen | Director Relations | Profile | |
| Leverne Marsh | Executive Marketing | Profile | |
| Jereme Sylvain | CFO VP | Profile | |
| Sadie Stern | Executive Officer | Profile |
About DexCom Management Performance
The success or failure of an entity such as DexCom Inc often depends on how effective the management is. DexCom management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of DexCom management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the DexCom management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.09 | 0.09 | |
| Return On Capital Employed | 0.13 | 0.13 | |
| Return On Assets | 0.09 | 0.09 | |
| Return On Equity | 0.26 | 0.27 |
The data published in DexCom's official financial statements usually reflect DexCom's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of DexCom Inc. For example, before you start analyzing numbers published by DexCom accountants, it's critical to develop an understanding of what DexCom's liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of DexCom's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, DexCom's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in DexCom's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of DexCom Inc. Please utilize our Beneish M Score to check the likelihood of DexCom's management manipulating its earnings.
DexCom Workforce Analysis
Traditionally, organizations such as DexCom use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare DexCom within its industry.DexCom Manpower Efficiency
Return on DexCom Manpower
| Revenue Per Employee | 381.3K | |
| Revenue Per Executive | 106.5M | |
| Net Income Per Employee | 57K | |
| Net Income Per Executive | 15.9M | |
| Working Capital Per Employee | 302.1K | |
| Working Capital Per Executive | 84.4M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for DexCom Stock analysis
When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.81 | Earnings Share 1.3 | Revenue Per Share 9.384 | Quarterly Revenue Growth 0.269 | Return On Assets 0.0641 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.